Rev‐erbα, a circadian repressor, decreases amyloid plaque number and size in the 5XFAD AD mouse model. Even Rev‐erbα show a neuroinflammatory effect, which proves Rev‐erbα as a novel therapeutic target. Here, NR1D1 is linked to Alzheimer disease.